Sentio Pharmaceuticals is a clinical-stage biotechnology company that develops oral small molecule therapies targeting G protein-coupled receptors (GPCRs), a major drug target class representing approximately one-third of all FDA-approved medicines. The company uses its proprietary Native Complex Platform to isolate and study full-length GPCR proteins in synthetic lipid environments, enabling structure-based drug discovery to address undrugged therapeutic targets in endocrinology, immunology, metabolic diseases, and other areas. Sentio generates revenue through research collaborations and licensing agreements with pharmaceutical partners who fund development and commercialization, supplemented by milestone payments and royalties on future product sales.